Published in Drugs on April 01, 2017
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
Pathogenesis of Escherichia coli diarrhea. N Engl J Med (1971) 10.36
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol (2013) 6.82
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA (2004) 6.06
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med (2016) 4.16
Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med (2011) 3.62
Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol (2012) 3.59
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One (2015) 3.46
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation (2013) 3.45
Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol (2000) 3.43
Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol (2016) 3.36
Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med (2010) 3.31
Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther (2015) 3.26
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos (2004) 3.04
Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut (2011) 3.02
Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology (2010) 3.00
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med (2005) 2.98
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90
Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut (2000) 2.67
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther (2015) 2.46
The Delphi technique in health sciences education research. Med Teach (2005) 2.37
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med (2006) 2.22
Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer (2014) 2.05
The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol (2009) 2.03
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ (2010) 2.03
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther (2003) 1.91
Proton pump inhibitors and gastric neoplasia. Gut (2006) 1.90
The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med (2001) 1.88
Global incidence of oesophageal cancer by histological subtype in 2012. Gut (2014) 1.84
Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med (2012) 1.83
Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther (2011) 1.83
Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome (2014) 1.82
Long-term safety concerns with proton pump inhibitors. Am J Med (2009) 1.81
Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol (2011) 1.80
Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther (2011) 1.76
Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol (2012) 1.69
Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology (2015) 1.69
Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther (2008) 1.68
Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut (2006) 1.67
Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology (2003) 1.65
Identifying patients with suspected gastro-oesophageal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract (2011) 1.63
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology (2010) 1.62
Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol (2007) 1.61
Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother (2007) 1.60
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology (2009) 1.59
Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect (2006) 1.57
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology (2010) 1.55
Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc (2015) 1.53
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther (2015) 1.51
Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study. Epidemiol Infect (2010) 1.50
Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther (2007) 1.45
Empirical treatment based on "typical" reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc (2002) 1.44
Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther (2003) 1.40
Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther (2009) 1.39
Mortality study of 18 000 patients treated with omeprazole. Gut (2003) 1.39
False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol (2012) 1.38
Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care (2010) 1.35
Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther (2008) 1.35
Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol (2015) 1.31
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int (2014) 1.30
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut (2013) 1.26
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol (2002) 1.23
Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med (1998) 1.22
Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM (2008) 1.22
Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res (2010) 1.21
Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther (2010) 1.21
Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta (1991) 1.20
Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev (2010) 1.19
Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One (2015) 1.17
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther (2003) 1.15
Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked. Surg Endosc (2006) 1.13
Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther (2012) 1.10
Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther (2003) 1.10
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol (2012) 1.08
Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther (2005) 1.08
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol (2008) 1.08
Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther (2004) 1.07
FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother (2012) 1.07
The response of early gastric cancer to proton-pump inhibitors. N Engl J Med (1998) 1.07
Acid-suppressive drugs and community-acquired pneumonia. Epidemiology (2009) 1.06
Prevention and self-treatment of traveler's diarrhea. Clin Microbiol Rev (2006) 1.05
Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf (2014) 1.05
Screening for gastric cancer: the usefulness of endoscopy. Clin Endosc (2014) 1.03
Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol (2013) 1.02
Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol (2013) 1.02
Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist (2012) 1.00
Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res (2010) 0.99
Gastric acid, calcium absorption, and their impact on bone health. Physiol Rev (2013) 0.99